Sign in
Taking peopleNo phase

One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei

Key facts

Who runs it
Beijing Tsinghua Chang Gung Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
132 people, planned
Started
1 Nov 2025
Expected to end
1 Nov 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • One HIPEC session
  • Three HIPEC sessions
Record updated
9 January 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Voluntarily consent to participate, sign informed consent, and be willing and able to comply with the study protocol
  • Age 18-70 years
  • Undergo CRS+HIPEC with pathological diagnosis of PMP of high grade with signet-ring cells, high grade, or low grade
  • Karnofsky performance status (KPS) >60
  • Adequate function of major organs as follows:; Hematology: WBC ≥3.5×10\^9/L, ANC ≥1.0×10\^9/L, LC ≥0.5×10\^9/L, PLT ≥80×10\^9/L, Hb ≥90 g/L; Hepatic function: AST, ALT, and TBIL ≤2×upper limit of normal (ULN); Renal function: serum creatinine <1.2×ULN; Coagulation: APTT ≤1.5×ULN; INR or PT ≤1.5×ULN; Cardiopulmonary function sufficient to tolerate major surgery and HIPEC; (5) Radiological Peritoneal Cancer Index (PCI) ≥15; (6) No local or systemic antitumor therapy within 1 month prior to CRS+HIPEC; (7) Adverse reactions from prior treatments have resolved before study initiation or, in the investigator's judgment, will not interfere with this study

Who cannot take part

  • Concomitant hematological disorders or other malignancies
  • Acute or subacute infectious disease
  • History of allergy to cisplatin or docetaxel, or marked allergic diathesis or severe allergy history
  • Psychiatric or psychological disorders preventing cooperation with treatment and efficacy evaluation
  • Any other condition deemed unsuitable for enrollment by the investigator
  • AST, ALT, or TBIL ≥2×ULN
  • Serum creatinine ≥1.2×ULN
  • Metastases to lung, brain, bone, or liver
  • Severe mesenteric contraction
  • Major organ dysfunction that cannot support the planned procedures

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Pseudomyxoma peritonei

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to compare the efficacy and safety of one versus three sessions of hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) for patients with pseudomyxoma peritonei (PMP).

Read full original descriptionShow less

The main questions it aims to answer are:

* Does receiving three HIPEC sessions lead to better Progression-Free Survival (PFS) and Overall Survival (OS) compared to one session? * What are the differences in postoperative complications (e.g., infection, bowel obstruction, myelosuppression) and organ toxicity (e.g., liver/kidney injury) between the two regimens? * How do the different treatment schedules impact patients' quality of life?

Researchers will compare the experimental group (3 HIPEC sessions) to the control group (1 HIPEC session) to investigate the efficacy and safety of the additional sessions.

Participants will:

* Be randomly assigned to one of two groups:

1. Control Group: Receive only a single intraoperative HIPEC session following CRS. 2. Experimental Group: Receive two additional HIPEC sessions after CRS+HIPEC (on post-operative day 2 and day 4) at reduced drug doses. * Undergo scheduled safety checks for side effects on days 1, 3, 5, 7, and 10 post-HIPEC. * Attend a follow-up visit at 1 month after CRS+HIPEC and, if eligible, receive 6 cycles of standard postoperative chemotherapy. * Attend regular long-term follow-up visits for several years, which will include physical examinations, blood tests (for tumor markers), CT scans, and quality-of-life questionnaires (EORTC QLQ-C30 version 3.0).

The 2 groups in the trial

  • Experimental GroupTreatment being tested

    Treatment: Three HIPEC sessions

  • Control GroupExisting treatment, for comparison

    Treatment: One HIPEC session

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of One vs Three Cycles of Hyperthermic Intraperitoneal Chemotherapy After Cytoreductive Surgery for Pseudomyxoma Peritonei: A Multicenter Randomized Controlled Study
Criteria questions
Built from NCT07328737, who can take part
Record updated
9 January 2026